CARsgen Therapeutics-B (02171): CT0596 Completes First Patient Infusion in China Phase I Registrational Clinical Trial

Zhitong Finance APP news, CARsgen Therapeutics-B (02171) announced that CT0596, a BCMA-targeting universal CAR-T cell product, has completed first patient dosing in a Phase I registrational clinical trial in China for the treatment of patients with relapsed/refractory multiple myeloma (R/R MM). The IIT study results of CT0596 have been presented as a poster at the 2026 European Hematology Association (EHA) Annual Congress.